Market Cap 1.48B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,323,100
Avg Vol 1,736,852
Day's Range N/A - N/A
Shares Out 88.77M
Stochastic %K 97%
Beta 0.84
Analysts Strong Sell
Price Target $33.67

Latest News on TVTX

Travere Therapeutics to Present at Upcoming Investor Conferences

Nov 25, 2024, 4:30 PM EST - 5 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences


Overlooked Stock: TVTX

Sep 9, 2024, 4:50 PM EDT - 8 months ago

Overlooked Stock: TVTX


Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30, 2024, 4:23 PM EDT - 8 months ago

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan